328 related articles for article (PubMed ID: 17483547)
21. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
[TBL] [Abstract][Full Text] [Related]
22. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates.
Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L
J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239
[TBL] [Abstract][Full Text] [Related]
23. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes.
Moura I; Spigaglia P; Barbanti F; Mastrantonio P
J Antimicrob Chemother; 2013 Feb; 68(2):362-5. PubMed ID: 23104495
[TBL] [Abstract][Full Text] [Related]
24. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors.
Sundram F; Guyot A; Carboo I; Green S; Lilaonitkul M; Scourfield A
J Hosp Infect; 2009 Jun; 72(2):111-8. PubMed ID: 19386381
[TBL] [Abstract][Full Text] [Related]
25. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.
Freeman J; Vernon J; Morris K; Nicholson S; Todhunter S; Longshaw C; Wilcox MH;
Clin Microbiol Infect; 2015 Mar; 21(3):248.e9-248.e16. PubMed ID: 25701178
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea.
Kim J; Kang JO; Kim H; Seo MR; Choi TY; Pai H; Kuijper EJ; Sanders I; Fawley W
Clin Microbiol Infect; 2013 Jun; 19(6):521-7. PubMed ID: 22712697
[TBL] [Abstract][Full Text] [Related]
28. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.
Kim J; Kang JO; Pai H; Choi TY
Int J Antimicrob Agents; 2012 Jul; 40(1):24-9. PubMed ID: 22578765
[TBL] [Abstract][Full Text] [Related]
29. Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1).
Fawley WN; Parnell P; Verity P; Freeman J; Wilcox MH
J Clin Microbiol; 2005 Jun; 43(6):2685-96. PubMed ID: 15956384
[TBL] [Abstract][Full Text] [Related]
30. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.
Goorhuis A; Bakker D; Corver J; Debast SB; Harmanus C; Notermans DW; Bergwerff AA; Dekker FW; Kuijper EJ
Clin Infect Dis; 2008 Nov; 47(9):1162-70. PubMed ID: 18808358
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
Freeman J; Baines SD; Jabes D; Wilcox MH
J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
[TBL] [Abstract][Full Text] [Related]
33. [Clostridium-difficile-associated infections].
Eckert C; Barbut F
Med Sci (Paris); 2010 Feb; 26(2):153-8. PubMed ID: 20188046
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of Clostridium difficile isolates from horses in an intensive care unit and association of disease severity with strain type.
Magdesian KG; Dujowich M; Madigan JE; Hansen LM; Hirsh DC; Jang SS
J Am Vet Med Assoc; 2006 Mar; 228(5):751-5. PubMed ID: 16506942
[TBL] [Abstract][Full Text] [Related]
35. Infection of hamsters with epidemiologically important strains of Clostridium difficile.
Sambol SP; Tang JK; Merrigan MM; Johnson S; Gerding DN
J Infect Dis; 2001 Jun; 183(12):1760-6. PubMed ID: 11372028
[TBL] [Abstract][Full Text] [Related]
36. Mixed infection by Clostridium difficile in an in vitro model of the human gut.
Baines SD; Crowther GS; Todhunter SL; Freeman J; Chilton CH; Fawley WN; Wilcox MH
J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280
[TBL] [Abstract][Full Text] [Related]
37. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Adams DA; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
[TBL] [Abstract][Full Text] [Related]
38. Detection of virulence genes of Clostridium difficile by multiplex PCR.
Antikainen J; Pasanen T; Mero S; Tarkka E; Kirveskari J; Kotila S; Mentula S; Könönen E; Virolainen-Julkunen AR; Vaara M; Tissari P
APMIS; 2009 Aug; 117(8):607-13. PubMed ID: 19664132
[TBL] [Abstract][Full Text] [Related]
39. A case-control study of community-associated Clostridium difficile infection.
Wilcox MH; Mooney L; Bendall R; Settle CD; Fawley WN
J Antimicrob Chemother; 2008 Aug; 62(2):388-96. PubMed ID: 18434341
[TBL] [Abstract][Full Text] [Related]
40. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
